Delayed
Nasdaq Stockholm
07:28:50 2024-06-10 am EDT
|
5-day change
|
1st Jan Change
|
1.134
SEK
|
-1.90%
|
|
+0.18%
|
+64.59%
|
Fiscal Period: December |
2019
|
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Capitalization
1 |
753.9
|
567.5
|
566.9
|
341.9
|
453.3
|
876.3
|
-
|
-
|
Enterprise Value (EV)
1 |
574
|
476.3
|
298.5
|
269.1
|
403.3
|
481.8
|
876.3
|
876.3
|
P/E ratio
|
-3.59
x
|
-3.96
x
|
-4.02
x
|
-1.76
x
|
-1.25
x
|
-2.54
x
|
-11.5
x
|
-30.3
x
|
Yield
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Capitalization / Revenue
|
140
x
|
85.1
x
|
37.5
x
|
9.21
x
|
7.32
x
|
3.36
x
|
7.16
x
|
7.07
x
|
EV / Revenue
|
106
x
|
71.4
x
|
19.7
x
|
7.25
x
|
6.52
x
|
1.84
x
|
7.16
x
|
7.07
x
|
EV / EBITDA
|
-2.83
x
|
-3.59
x
|
-2.29
x
|
-1.49
x
|
-1.69
x
|
80.8
x
|
-10.5
x
|
-13.9
x
|
EV / FCF
|
-3.17
x
|
-3.37
x
|
-2.35
x
|
-1.56
x
|
-2.1
x
|
-2.4
x
|
-4.47
x
|
-13.3
x
|
FCF Yield
|
-31.6%
|
-29.7%
|
-42.6%
|
-64.3%
|
-47.5%
|
-41.7%
|
-22.4%
|
-7.53%
|
Price to Book
|
2.92
x
|
4.92
x
|
2.01
x
|
3.88
x
|
34.5
x
|
2.46
x
|
-
|
-
|
Nbr of stocks (in thousands)
|
71,389
|
71,389
|
220,585
|
220,585
|
657,954
|
758,039
|
-
|
-
|
Reference price
2 |
10.56
|
7.950
|
2.570
|
1.550
|
0.6890
|
1.156
|
1.156
|
1.156
|
Announcement Date
|
2/12/20
|
2/26/21
|
2/11/22
|
2/10/23
|
2/8/24
|
-
|
-
|
-
|
Fiscal Period: December |
2019
|
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Net sales
1 |
5.396
|
6.666
|
15.13
|
37.14
|
61.9
|
261.2
|
122.4
|
123.9
|
EBITDA
1 |
-203
|
-132.8
|
-130.4
|
-181
|
-238.5
|
5.963
|
-83.72
|
-62.82
|
EBIT
1 |
-214.5
|
-144.3
|
-141.6
|
-192.8
|
-249
|
-2.287
|
-90.22
|
-69.32
|
Operating Margin
|
-3,975.17%
|
-2,164.69%
|
-936.14%
|
-519.16%
|
-402.22%
|
-0.88%
|
-73.73%
|
-55.96%
|
Earnings before Tax (EBT)
1 |
-210.1
|
-143.3
|
-141.7
|
-193.4
|
-248.6
|
-6.113
|
-89.72
|
-68.82
|
Net income
1 |
-210.1
|
-143.3
|
-141.7
|
-193.4
|
-248.6
|
-6.113
|
-89.72
|
-68.82
|
Net margin
|
-3,893.85%
|
-2,149.65%
|
-936.8%
|
-520.81%
|
-401.58%
|
-2.34%
|
-73.32%
|
-55.56%
|
EPS
2 |
-2.940
|
-2.010
|
-0.6400
|
-0.8800
|
-0.5500
|
-0.4553
|
-0.1003
|
-0.0382
|
Free Cash Flow
1 |
-181.1
|
-141.5
|
-127.1
|
-173
|
-191.7
|
-201
|
-196
|
-66
|
FCF margin
|
-3,357.08%
|
-2,122.02%
|
-840.13%
|
-465.99%
|
-309.76%
|
-76.96%
|
-160.16%
|
-53.28%
|
FCF Conversion (EBITDA)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
FCF Conversion (Net income)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Dividend per Share
2 |
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Announcement Date
|
2/12/20
|
2/26/21
|
2/11/22
|
2/10/23
|
2/8/24
|
-
|
-
|
-
|
Fiscal Period: December |
2019
|
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Net Debt
1 |
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Net Cash position
1 |
180
|
91.3
|
268
|
72.8
|
50
|
395
|
-
|
-
|
Leverage (Debt/EBITDA)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Free Cash Flow
1 |
-181
|
-141
|
-127
|
-173
|
-192
|
-201
|
-196
|
-66
|
ROE (net income / shareholders' equity)
|
-57.8%
|
-76.7%
|
-71.3%
|
-104%
|
-493%
|
-88.1%
|
-1,417%
|
-
|
ROA (Net income/ Total Assets)
|
-51.3%
|
-61.9%
|
-58.4%
|
-76.9%
|
-173%
|
-193%
|
-169%
|
-74.9%
|
Assets
1 |
409.6
|
231.5
|
242.5
|
251.4
|
144
|
3.163
|
53.12
|
91.89
|
Book Value Per Share
2 |
3.620
|
1.610
|
1.280
|
0.4000
|
0.0200
|
0.4700
|
-
|
-
|
Cash Flow per Share
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Capex
1 |
2.07
|
0.1
|
0.05
|
0.44
|
2.46
|
0.03
|
-
|
-
|
Capex / Sales
|
38.34%
|
1.53%
|
0.3%
|
1.18%
|
3.97%
|
0.01%
|
-
|
-
|
Announcement Date
|
2/12/20
|
2/26/21
|
2/11/22
|
2/10/23
|
2/8/24
|
-
|
-
|
-
|
Last Close Price
1.156
SEK Average target price
1.9
SEK Spread / Average Target +64.36% Consensus |
1st Jan change
|
Capi.
|
---|
| +64.59% | 83.14M | | +51.85% | 57.87B | | +41.53% | 40.25B | | -5.25% | 39.94B | | -5.16% | 28.54B | | +12.79% | 26.4B | | -20.18% | 19.33B | | +30.88% | 12.4B | | +0.61% | 12.23B | | +25.06% | 12.2B |
Other Biotechnology & Medical Research
|